Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.

Also called NCT04680442

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 130 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04680442
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil, Canada, Russia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04680442. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-01 (actual); primary completion 2025-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Acronym
SCHOLAR-2
Condition
Breast Cancer
Condition
Heart Failure
Intervention (Drug)
Trastuzumab
Intervention (Drug)
Pertuzumab
Intervention (Drug)
Trastuzumab emtansine
Lead sponsor
Population Health Research Institute (class: other)

Record details

Record id
cardio:ct-nct04680442
Content hash
2d923610d1e284ff8c66fa20d7c83941212f7cd4a315e3559ce6fd234a07dce4